Why the study?
Does incomplete inhibition of platelet function assessed by PFA-100 identify high residual platelet response in cardiovascular patients on chronic aspirin therapy?
Does incomplete inhibition of platelet function assessed by PFA-100 identify high residual platelet response in cardiovascular patients on chronic aspirin therapy?
Platelet function tests partially dependent on COX-1, such as PFA-100, may better identify patients on aspirin with persistent platelet reactivity and higher vascular risk compared to strictly COX-1-dependent tests.
No takes yet. Share an insight, caveat, or question.
PFA-100 incomplete inhibition was associated with higher residual reactivity in recurrent-event patients on aspirin; leaves open whether it improves risk stratification over COX-1 tests.
Crescente et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: